Multiple Myeloma Clinical Trials in Atlanta

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +43 more
2022-03-28
Mar 28, 2022
N
Reduced Intensity Conditioning Transplant Using Haploidentical Donors - 2020
Completed
  • Chronic Myelogenous Leukemia
  • +9 more
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
G
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruiting
  • Multiple Myeloma
  • +2 more
  • Denver, Colorado
  • +11 more
2022-04-04
Apr 4, 2022
N
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma - 2021
Completed
  • Multiple Myeloma
  • Atlanta, Georgia
    Blood and Marrow Transplant Group of Georgia
2022-04-04
Apr 4, 2022
T
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)Therapy. A Phase 3, Randomized, Placebo-Controlled.
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Fountain Valley, California
  • +277 more
2022-03-23
Mar 23, 2022
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2022-03-21
Mar 21, 2022
P
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +45 more
2022-03-29
Mar 29, 2022
J
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +33 more
2022-03-24
Mar 24, 2022
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2022-03-24
Mar 24, 2022
J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +56 more
2022-03-24
Mar 24, 2022
J
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +106 more
2022-03-24
Mar 24, 2022
J
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Daratumumab IV
  • +3 more
  • Birmingham, Alabama
  • +211 more
2022-03-24
Mar 24, 2022
J
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +81 more
2022-03-24
Mar 24, 2022
J
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +158 more
2022-03-24
Mar 24, 2022
C
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruiting
  • Multiple Myeloma
  • bb2121 carfilzomib
  • +3 more
  • Scottsdale, Arizona
  • +18 more
2022-03-23
Mar 23, 2022
J
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +35 more
2022-03-24
Mar 24, 2022
J
A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Daratumumab Subcutaneous (SC) Administration
  • Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
  • Atlanta, Georgia
  • +11 more
2022-03-24
Mar 24, 2022
J
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +28 more
2022-03-24
Mar 24, 2022
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2022-03-24
Mar 24, 2022
G
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +5 more
  • Atlanta, Georgia
  • +41 more
2022-03-23
Mar 23, 2022
R
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Miami, Florida
  • +21 more
2022-03-22
Mar 22, 2022
N
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Recruiting
  • Multiple Myeloma
  • +2 more
  • Goodyear, Arizona
  • +16 more
2022-03-18
Mar 18, 2022
G
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Birmingham, Alabama
  • +31 more
2022-03-21
Mar 21, 2022
B
Expanded Access Treatment Protocol CA204-143
No longer available
  • Multiple Myeloma
  • Elotuzumab in combination with Lenalidomide and Dexamethasone
  • Concord, California
  • +26 more
2022-03-17
Mar 17, 2022
G
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • San Francisco, California
  • +5 more
2022-03-17
Mar 17, 2022